PHAXIAM Therapeutics (BATS-CHIXE:PHXMP) - Stock Price, News & Analysis

PHXMP Stock Overview

A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. More details

PHXMP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Does not have a meaningful market cap (€17M)

Does not have meaningful revenue (€1M)

+ 1 more risk

PHAXIAM Therapeutics S.A. Competitors

ProBiotix Health

OFEX:PBX

UK£10.3m

Verici Dx

AIM:VRCI

UK£8.2m

Genflow Biosciences

LSE:GENF

UK£6.1m

Oncimmune Holdings

AIM:ONC

UK£17.2m

Price History & Performance

Summary of all time highs, changes and price drops for PHAXIAM Therapeutics
Historical stock prices
Current Share Price	€2.21
52 Week High	€0
52 Week Low	€0
Beta	1.86
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-95.62%
Change since IPO	-97.85%

Recent updates

Shareholder Returns

	PHXMP	GB Biotechs	GB Market
7D	0%	2.0%	1.7%
1Y	n/a	-17.5%	8.3%

Return vs Industry: Insufficient data to determine how PHXMP performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how PHXMP performed against the UK Market.

Price Volatility

Is PHXMP's price volatile compared to industry and market?
PHXMP volatility
PHXMP Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: PHXMP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PHXMP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	68	Thibaut Fayet	www.phaxiam.com

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.

PHAXIAM Therapeutics S.A. Fundamentals Summary

How do PHAXIAM Therapeutics's earnings and revenue compare to its market cap?
PHXMP fundamental statistics
Market cap	€16.79m
Earnings (TTM)	-€23.49m
Revenue (TTM)	€1.33m

12.7x

P/S Ratio

-0.7x

P/E Ratio

Is PHXMP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHXMP income statement (TTM)
Revenue	€1.33m
Cost of Revenue	€0
Gross Profit	€1.33m
Other Expenses	€24.81m
Earnings	-€23.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 25, 2024

Earnings per share (EPS)	-2.35
Gross Margin	100.00%
Net Profit Margin	-1,771.34%
Debt/Equity Ratio	39.8%

How did PHXMP perform over the long term?

See historical performance and comparison

PHXMP Stock Overview

Risk Analysis

PHAXIAM Therapeutics S.A. Competitors

OFEX:PBX

UK£10.3m

AIM:VRCI

UK£8.2m

LSE:GENF

UK£6.1m

AIM:ONC

UK£17.2m

Price History & Performance

Recent News & Updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

No longer forecast to breakeven

No longer forecast to breakeven

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Shareholder Returns

Price Volatility

About the Company

PHAXIAM Therapeutics S.A. Fundamentals Summary

12.7x

-0.7x

Earnings & Revenue